AMGN

AMGEN TO WEBCAST INVESTOR CALL AT ESMO 2023

Retrieved on: 
Thursday, October 19, 2023
AACR, ESMO, Congress, European Society for Medical Oncology, Conference, Internet, Webcast, Oncology, AMGN, European Society of Gynaecological Oncology, Calendar, AMG, Pharmaceutical industry, Broadcasting, Cryptocurrency, Research, Amgen

THOUSAND OAKS, Calif., Oct. 19, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will host a webcasted call for the investment community at 8:00 a.m.

Key Points: 
  • THOUSAND OAKS, Calif., Oct. 19, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will host a webcasted call for the investment community at 8:00 a.m.
  • David M. Reese, M.D., executive vice president of Research and Development at Amgen, members of Amgen's development team as well as clinical investigators will participate.
  • The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors.
  • Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar.

AMGEN TO PRESENT NEW RESEARCH FROM ONCOLOGY PORTFOLIO AND PIPELINE AT ESMO 2023

Retrieved on: 
Monday, October 16, 2023
Keypad, Abstract, Breast cancer, FOLFIRI, Oncology, ESMO, SD, Carcinoma, Colorectal cancer, European Society for Medical Oncology, AMGN, Cancer, KRAS, Myalgia, Cytokine release syndrome, RAS, Hitachi HD44780 LCD controller, MA, Prostate cancer, PR, Love at First Bite, NSCLC, PAN, SCLC, Fever, CRC, Denosumab, Fatigue, CRS, Renal cell carcinoma, ESME, Heath Robinson (codebreaking machine), Congress, Biomarker, AMG, Research and development, Panitumumab, Pembrolizumab, AM, Metastasis, STEAP1, Prostate, Pharmaceutical industry, Medical imaging, Book, Entertainment, Communications satellite, Research, Amgen, Patient

THOUSAND OAKS, Calif., Oct. 16, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data across its broad oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress 2023, taking place from October 20-24 in Madrid. Results from Amgen-sponsored and collaborative studies, including two late-breaking oral presentations, will feature data in a range of tough-to-treat cancers.

Key Points: 
  • Results from Amgen-sponsored and collaborative studies, including two late-breaking oral presentations, will feature data in a range of tough-to-treat cancers.
  • "Our data at ESMO demonstrate the rapid progress we are making in advancing a portfolio with first-in-class therapies, including metastatic KRAS G12C mutated colorectal cancer and small cell lung cancer," said David M. Reese, M.D., executive vice president of Research and Development at Amgen.
  • "These findings illustrate how we are attacking cancer from many different angles to deliver new approaches poised to alter the natural history of disease across many cancers."
  • Amgen will present data from two late-breaking abstracts at ESMO:
    Results from CodeBreaK 300 (Abstract #LBA10), a global, registration-enabling Phase 3 trial evaluating LUMAKRAS (sotorasib) combined with Vectibix (panitumumab) in chemorefractory KRAS G12C-mutated metastatic CRC.

Large-scale proteomics in population-based studies from UK and Iceland

Retrieved on: 
Wednesday, October 4, 2023
AMGN, UK Biobank, Genetic distance, Genetics, UKB, Proteome, Biomarker, Proteomics, Kingdom of Poland, Plasma, Protein, DeCODE genetics, Paper, Genome, Disease, Vaccine, Amgen, Nature

REYKJAVIK, Iceland, Oct. 4, 2023 /PRNewswire/ -- In a paper released today, deCODE Genetics' scientists shared their findings from a plasma proteomics study performed using affinity-based methods.

Key Points: 
  • REYKJAVIK, Iceland, Oct. 4, 2023 /PRNewswire/ -- In a paper released today, deCODE Genetics' scientists shared their findings from a plasma proteomics study performed using affinity-based methods.
  • The study's focus on the plasma proteome led the team to find associations between various diseases and the levels of specific proteins.
  • The data were generated by the UK Biobank Pharma Proteomics Project (UKB-PPP), a consortium of thirteen biopharmaceutical companies, including Amgen, studying circulating protein biomarkers.
  • By examining large cohorts in Iceland and the UK, a substantial number of associations could be detected, making the comparison meaningful.

Large-scale proteomics in population-based studies from UK and Iceland

Retrieved on: 
Wednesday, October 4, 2023
AMGN, UK Biobank, Genetic distance, Genetics, UKB, Proteome, Biomarker, Proteomics, Kingdom of Poland, Plasma, Protein, DeCODE genetics, Paper, Genome, Disease, Vaccine, Amgen, Nature

REYKJAVIK, Iceland, Oct. 4, 2023 /PRNewswire/ -- In a paper released today, deCODE Genetics' scientists shared their findings from a plasma proteomics study performed using affinity-based methods.

Key Points: 
  • REYKJAVIK, Iceland, Oct. 4, 2023 /PRNewswire/ -- In a paper released today, deCODE Genetics' scientists shared their findings from a plasma proteomics study performed using affinity-based methods.
  • The study's focus on the plasma proteome led the team to find associations between various diseases and the levels of specific proteins.
  • The data were generated by the UK Biobank Pharma Proteomics Project (UKB-PPP), a consortium of thirteen biopharmaceutical companies, including Amgen, studying circulating protein biomarkers.
  • By examining large cohorts in Iceland and the UK, a substantial number of associations could be detected, making the comparison meaningful.

INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Amgen Inc’s Directors and Officers for Breach of Fiduciary Duties – AMGN

Retrieved on: 
Wednesday, September 20, 2023
AMGN, Law, IRS, News, Average revenue per user, Internal Revenue Service, Management, Amgen

NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of Amgen Inc. (“Amgen”) (NASDAQ: AMGN) breached their fiduciary duties to Amgen and its shareholders.

Key Points: 
  • NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of Amgen Inc. (“Amgen”) (NASDAQ: AMGN) breached their fiduciary duties to Amgen and its shareholders.
  • If you are an Amgen shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982, or [email protected] .
  • Scott+Scott is investigating whether members of Amgen’s board of directors or senior management failed to manage Amgen in an acceptable manner, in breach of their fiduciary duties to Amgen, and whether Amgen and its shareholders have suffered damages as a result.
  • If you are an Amgen shareholder, you may have legal claims against Amgen’s directors and officers.

Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty

Retrieved on: 
Friday, September 22, 2023
AMGN, KRAS, Gastrointestinal cancer, Amgen, Optimism, DOR, National Institutes of Health, Bangladesh Technical Education Board, Congress, Patient, Risk, Corr, H. Lee Moffitt Cancer Center & Research Institute, News, Disease, Carcinoma, Oncolytics Biotech, European Hematology Association, Hope, Lung cancer, ONC, Hematology, TSX, Bone marrow, BTC, The Lancet, FDA, Polycythemia, NIH, Safety, Docetaxel, Abstract, Eye, Cancer, NSCLC, PFS, Psoriasis, MD Anderson Cancer Center, Breakthrough therapy, Colorectal cancer, University, Cancer Moonshot, Therapy, ORR, Partnership, CRC, Progression-free survival, RBC Capital Markets, OS, Paclitaxel, SCLC, ASCO, Pelareorep, EHA, Jazz Pharmaceuticals, Breast cancer, Pharmaceutical industry, Birth control, Vaccine, Medical imaging, Protagonist, Research

VANCOUVER, British Columbia, Sept. 22, 2023 /PRNewswire/ -- USA News Group - Despite the potential federal funding challenges due to the recent debt ceiling deal, optimism in the battle against cancer persists, thanks in large part to the audacious "Cancer Moonshot" initiative. This ambitious plan, aimed at halving cancer rates within the next quarter-century, continues to fuel hope even as concerns about the stability of National Institutes of Health (NIH) funding arise. In these turbulent times, the resilience and ingenuity of the biotech sector provide a beacon of hope. For instance, Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Zymeworks Inc. (NASDAQ: ZYME), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Protagonist Therapeutics, Inc. (NASDAQ: PTGX), and Amgen Inc. (NASDAQ: AMGN), have each demonstrated inspiring progress and unwavering commitment in advancing cancer treatments, highlighting their vital role in the future of cancer therapy.

Key Points: 
  • The oral presentation shared at the event described how they've been testing a treatment for advanced breast cancer, and it's looking very promising.
  • The treatment combines Oncolytics' flagship drug, pelareorep, with a well-known cancer medicine, paclitaxel.
  • Pelareorep is a unique drug that targets and kills cancer cells by making them self-destruct while leaving healthy cells unharmed.
  • It even lowered the risk of the cancer getting worse by a significant 71% compared to just using paclitaxel.

Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty

Retrieved on: 
Friday, September 22, 2023
AMGN, KRAS, Gastrointestinal cancer, Amgen, Optimism, DOR, National Institutes of Health, Bangladesh Technical Education Board, Congress, Patient, Risk, Corr, H. Lee Moffitt Cancer Center & Research Institute, News, Disease, Carcinoma, Oncolytics Biotech, European Hematology Association, Hope, Lung cancer, ONC, Hematology, TSX, Bone marrow, BTC, The Lancet, FDA, Polycythemia, NIH, Safety, Docetaxel, Abstract, Eye, Cancer, NSCLC, PFS, Psoriasis, MD Anderson Cancer Center, Breakthrough therapy, Colorectal cancer, University, Cancer Moonshot, Therapy, ORR, Partnership, CRC, Progression-free survival, RBC Capital Markets, OS, Paclitaxel, SCLC, ASCO, Pelareorep, EHA, Jazz Pharmaceuticals, Breast cancer, Pharmaceutical industry, Birth control, Vaccine, Medical imaging, Protagonist, Research

VANCOUVER, British Columbia, Sept. 22, 2023 /PRNewswire/ -- USA News Group - Despite the potential federal funding challenges due to the recent debt ceiling deal, optimism in the battle against cancer persists, thanks in large part to the audacious "Cancer Moonshot" initiative. This ambitious plan, aimed at halving cancer rates within the next quarter-century, continues to fuel hope even as concerns about the stability of National Institutes of Health (NIH) funding arise. In these turbulent times, the resilience and ingenuity of the biotech sector provide a beacon of hope. For instance, Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Zymeworks Inc. (NASDAQ: ZYME), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Protagonist Therapeutics, Inc. (NASDAQ: PTGX), and Amgen Inc. (NASDAQ: AMGN), have each demonstrated inspiring progress and unwavering commitment in advancing cancer treatments, highlighting their vital role in the future of cancer therapy.

Key Points: 
  • The oral presentation shared at the event described how they've been testing a treatment for advanced breast cancer, and it's looking very promising.
  • The treatment combines Oncolytics' flagship drug, pelareorep, with a well-known cancer medicine, paclitaxel.
  • Pelareorep is a unique drug that targets and kills cancer cells by making them self-destruct while leaving healthy cells unharmed.
  • It even lowered the risk of the cancer getting worse by a significant 71% compared to just using paclitaxel.

Variants in the genome interact with each other and with the environment to affect risk of cardiovascular disease

Retrieved on: 
Thursday, September 14, 2023
AMGN, Genetic distance, Genetics, Cholesterol, Cardiovascular disease, Drinking, University of Copenhagen, Metabolism, Risk, LDL, Cell, Paper, Coronary artery disease, Health, Apolipoprotein B, Icelandic, APOE2, Environment, Alzheimer's disease, Copenhagen University Library, Genome, Disease, Complex, Pharmaceutical industry, Vaccine, Amgen

The work described in the paper is based on searching for variants in the genome that associate with variance in quantitative traits and the assumption that those variants must interact either with other variants or components of the environment.

Key Points: 
  • The work described in the paper is based on searching for variants in the genome that associate with variance in quantitative traits and the assumption that those variants must interact either with other variants or components of the environment.
  • It is well established that the "bad" cholesterol (also called non-HDL cholesterol and LDL cholesterol) directly contributes to the development of cardiovascular disease.
  • The environment and the genome both influence bad cholesterol and consequently cardiovascular health.
  • Similarly, the authors show that variants in the genome interact with each other to affect cholesterol levels.

Variants in the genome interact with each other and with the environment to affect risk of cardiovascular disease

Retrieved on: 
Thursday, September 14, 2023
AMGN, Genetic distance, Genetics, Cholesterol, Cardiovascular disease, Drinking, University of Copenhagen, Metabolism, Risk, LDL, Cell, Paper, Coronary artery disease, Health, Apolipoprotein B, Icelandic, APOE2, Environment, Alzheimer's disease, Copenhagen University Library, Genome, Disease, Complex, Pharmaceutical industry, Vaccine, Amgen

The work described in the paper is based on searching for variants in the genome that associate with variance in quantitative traits and the assumption that those variants must interact either with other variants or components of the environment.

Key Points: 
  • The work described in the paper is based on searching for variants in the genome that associate with variance in quantitative traits and the assumption that those variants must interact either with other variants or components of the environment.
  • It is well established that the "bad" cholesterol (also called non-HDL cholesterol and LDL cholesterol) directly contributes to the development of cardiovascular disease.
  • The environment and the genome both influence bad cholesterol and consequently cardiovascular health.
  • Similarly, the authors show that variants in the genome interact with each other to affect cholesterol levels.

AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE

Retrieved on: 
Monday, September 11, 2023
AMGN, Webcast, Calendar, Bank, Conference, Internet, BST, Cryptocurrency, Broadcasting, Amgen

THOUSAND OAKS, Calif., Sept. 11, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 11:40 a.m. BST on Thursday, Sept. 14, 2023.

Key Points: 
  • THOUSAND OAKS, Calif., Sept. 11, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 11:40 a.m. BST on Thursday, Sept. 14, 2023.
  • Peter H. Griffith, executive vice president and chief financial officer at Amgen will present at the conference.
  • The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.
  • Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar.